<DOC>
	<DOC>NCT00014729</DOC>
	<brief_summary>OBJECTIVES: I. Determine the safety of isotretinoin in patients with recessive dystrophic epidermolysis bullosa.</brief_summary>
	<brief_title>Phase I Study of Isotretinoin in Patients With Recessive Dystrophic Epidermolysis Bullosa</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Patients receive oral isotretinoin daily for 8 months in the absence of disease progression or unacceptable toxicity. Completion date provided represents the completion date of the grant per OOPD records</detailed_description>
	<mesh_term>Epidermolysis Bullosa</mesh_term>
	<mesh_term>Epidermolysis Bullosa Dystrophica</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Diagnosis of recessive dystrophic epidermolysis bullosa (RDEB) RDEB HallopeauSiemens OR RDEB nonHallopeauSiemens Concurrent enrollment in the National Epidermolysis Bullosa Registry No regional or distant metastasis in patients with previous or concurrent squamous cell carcinoma Patient Characteristics Hepatic: No clinically significant hypertriglyceridemia No clinically significant hepatic dysfunction Renal: No clinically significant renal dysfunction Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2001</verification_date>
	<keyword>dermatologic disorders</keyword>
	<keyword>epidermolysis bullosa</keyword>
	<keyword>genetic diseases and dysmorphic syndromes</keyword>
	<keyword>rare disease</keyword>
</DOC>